Not provided
Not provided
Not provided
Not provided
Not provided
There are no sufficient patients in the hospital.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The investigators conduct this study to investigate whether oral administration of Dimethyl Fumarate, a Food and Drug Administration-approved drug for multiple sclerosis, is safe and effective in alleviating PHE and neurologic deficits in patients with ICH.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| standard management plus Dimethyl Fumarate | Experimental |
| |
| standard management plus placebo | Placebo Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Dimethyl fumarate | Drug | Dimethyl fumarate 240mg orally twice daily for 3 consecutive days |
|
| Measure | Description | Time Frame |
|---|---|---|
| Volume of Perihematomal edema(PHE) | measured by MRI | day7 |
| Glasgow Coma Scale (GCS) | The GCS score ranges from 3 to 15 points. The lower the score, the more severe the patient's coma is. | day7 |
| National Institutes of Health Stroke Scale (NIHSS) | The NIHSS score ranges from 0 to 42 points. The higher the score, the more severe the neurological impairment. | day 7 |
| Measure | Description | Time Frame |
|---|---|---|
| Volume of Perihematomal edema(PHE) | measured by MRI | day1 |
| Volume of Perihematomal edema(PHE) | measured by MRI | day3 |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Xuanwu Hospital, Beijing | Beijing | Beijing Municipality | 100053 | China |
Not provided
| ID | Term |
|---|---|
| D002543 | Cerebral Hemorrhage |
| D009461 | Neurologic Manifestations |
| ID | Term |
|---|---|
| D020300 | Intracranial Hemorrhages |
| D002561 | Cerebrovascular Disorders |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000069462 | Dimethyl Fumarate |
| ID | Term |
|---|---|
| D005650 | Fumarates |
| D003998 | Dicarboxylic Acids |
| D000144 | Acids, Acyclic |
| D002264 | Carboxylic Acids |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo | Drug | Placebo 240mg orally twice daily for 3 consecutive days |
|
| Volume of Perihematomal edema(PHE) | measured by MRI | day14 |
| Volume of Perihematomal edema(PHE) | measured by MRI | day90 |
| Glasgow Coma Scale (GCS) | The GCS score ranges from 3 to 15 points. The lower the score, the more severe the patient's coma is. | day 1 |
| Glasgow Coma Scale (GCS) | The GCS score ranges from 3 to 15 points. The lower the score, the more severe the patient's coma is. | day 3 |
| Glasgow Coma Scale (GCS) | The GCS score ranges from 3 to 15 points. The lower the score, the more severe the patient's coma is. | day 14 |
| National Institutes of Health Stroke Scale (NIHSS) | The NIHSS score ranges from 0 to 42 points. The higher the score, the more severe the neurological impairment. | day1 |
| National Institutes of Health Stroke Scale (NIHSS) | The NIHSS score ranges from 0 to 42 points. The higher the score, the more severe the neurological impairment. | day3 |
| National Institutes of Health Stroke Scale (NIHSS) | The NIHSS score ranges from 0 to 42 points. The higher the score, the more severe the neurological impairment. | day14 |
| National Institutes of Health Stroke Scale (NIHSS) | The NIHSS score ranges from 0 to 42 points. The higher the score, the more severe the neurological impairment. | day90 |
| The Modified Rankin Scale (mRS) | The mRS score ranges from 0 to 7 points. The higher the score, the more severe the neurological recovery state of stroke patients. | day1 |
| The Modified Rankin Scale (mRS) | The mRS score ranges from 0 to 7 points. The higher the score, the more severe the neurological recovery state of stroke patients. | day3 |
| The Modified Rankin Scale (mRS) | The mRS score ranges from 0 to 7 points. The higher the score, the more severe the neurological recovery state of stroke patients. | day7 |
| The Modified Rankin Scale (mRS) | The mRS score ranges from 0 to 7 points. The higher the score, the more severe the neurological recovery state of stroke patients. | day14 |
| The Modified Rankin Scale (mRS) | The mRS score ranges from 0 to 7 points. The higher the score, the more severe the neurological recovery state of stroke patients. | day90 |
| The Modified Barthel Index (mBI) | The mBI score ranges from 0 to 100 points. The higher the score, the higher the degree of independence of stroke patients. | day 1 |
| The Modified Barthel Index (mBI) | The mBI score ranges from 0 to 100 points. The higher the score, the higher the degree of independence of stroke patients. | day 3 |
| The Modified Barthel Index (mBI) | The mBI score ranges from 0 to 100 points. The higher the score, the higher the degree of independence of stroke patients. | day 7 |
| The Modified Barthel Index (mBI) | The mBI score ranges from 0 to 100 points. The higher the score, the higher the degree of independence of stroke patients. | day 14 |
| The Modified Barthel Index (mBI) | The mBI score ranges from 0 to 100 points. The higher the score, the higher the degree of independence of stroke patients. | day 90 |
| D009422 | Nervous System Diseases |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D006470 | Hemorrhage |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D012816 | Signs and Symptoms |
| D009930 |
| Organic Chemicals |